Document is current
Any future updates will be listed below
-
Authors
Mueller, Simon
Wintergerst, Maximilian W. M.
Falahat, Peyman
Holz, Frank G.
Schaefer, Christian
Schahab, Nadjib
Finger, Robert P.
Schultz, Thomas
-
Funding
Funding for this research was provided by:
BONFOR GEROK (O-137.0028)
DigiSight Technologies
Heine Optotechnik
ASKIN & CO GmbH
Berlin-Chemie AG
Acucela
Allergan
Apellis
Bayer
Bioeq/Formycon
CenterVue
Ellex
Roche/Genentech
Geuder
Kanghong
NightStarx
Novartis Pharma
Optos
Zeiss
Else Kröner-Fresenius-Stiftung/German Scholars Organization
Rheinische Friedrich-Wilhelms-Universität Bonn
- License Information
-
More Information
Article History
Received: 20 September 2021
Accepted: 7 January 2022
First Online: 26 January 2022
Competing interests
: M.W.M.W. received a travel grant and imaging devices from DigiSight Technologies, was a consultant for and received a grant, travel reimbursements and imaging devices from Heine Optotechnik, received honoraria and travel reimbursements from ASKIN & CO GmbH, a grant and travel reimbursements from Berlin-Chemie AG, free automated analyses from Eyenuk Inc., and imaging devices from D-EYE. Finger RP was a consultant for Bayer, Novartis, Santen, Opthea, Novelion, Retina Implant, and Oxford Innovation. Frank G. Holz: Research Grant Support: Acucela, Allergan, Apellis, Bayer, Bioeq/Formycon, CenterVue, Ellex, Roche/Genentech, Geuder, Kanghong, NightStarx, Novartis, Optos, Zeiss; Consultant: Acucela, Aerie, Allergan, Apellis, Bayer, Boehringer-Ingelheim, ivericbio, Roche/Genentech, Geuder, Grayburg Vision, ivericbio, LinBioscience, Kanghong, Novartis, Pixium Vision, Oxurion, Stealth BioTherapeutics, Zeiss. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. S.M, P.F., C.S. N.S. and T.S. have no competing interests.
